EUVIMEDEUVIMED entdecken
Open Access

The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial

Mostafa Najafipour iD, Farzad Najafipour iD, Alireza Ostadrahimi, Maryam Ghavami, Zohreh Razaghi, Helda Tutunchi, Naimeh Mesri Alamdari iD

Health Promotion Perspectives · 30.12.2024 · 14 (4) · 380-387

DOI: 10.34172/hpp.42486 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Promotion Perspectives, online erschienen am 30.12.2024. Verfasst von Mostafa Najafipour und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Azad Ardabil University of Medical Sciences, Ardabil, Iran. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter-2 (SGLT-2) acts as a key element in the reabsorption of glucose in the kidney. Currently, SGLT-2 inhibitors are FDA-approved for the treatment of type 2 diabetes. It is suggested that the mechanism of action may operate in the treatment of type 1 diabetes mellitus (T1DM), as well. This study aimed to evaluate the application of empagliflozin as an adjunctive to insulin in patients with T1D.

Methods

In this double-blind placebo-controlled randomized clinical study, 60 type 1 diabetic patients were randomly assigned to have either once-daily empagliflozin 10 mg or placebo, as an addition to insulin for 12 weeks. The hemoglobin A1C, fasting blood sugar (FBS), 2-hour post-prandial blood sugar, and anthropometric indices were measured before and after 12 weeks intervention.

Results

After 12 weeks, empagliflozin resulted in significant reductions of hemoglobin A1C -0.18 (95% CI: -0.37, 0.005, P=0.009), FBS –2.60 mg/dL (95% CI: -6.48, 1.28, P=0.035), 2-hour post-prandial blood sugar -22.56 mg/dL (95% CI: -35.15, 8.97, P

Schlagwörter

Stichwörter der Autor:innen

EmpagliflozinSodium-glucose transporter 2 InhibitorsType 1 diabetes

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, Azad Ardabil University of Medical Sciences, Ardabil, Iran.
  • Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Nutrition Research Center, Department of Clinical Nutrition, Faculty of Nutrition and Food Science, Tabriz University of Medical Sciences, Tabriz, Iran.

ORCID-Profile: Mostafa Najafipour, Farzad Najafipour, Naimeh Mesri Alamdari

Zitieren

APA

Najafipour, M., Najafipour, F., Ostadrahimi, A., Ghavami, M., Razaghi, Z., Tutunchi, H., & Mesri Alamdari, N. (2024). The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. Health Promotion Perspectives, 14(4), 380-387. https://doi.org/10.34172/hpp.42486

Vancouver

Najafipour M, Najafipour F, Ostadrahimi A, Ghavami M, Razaghi Z, Tutunchi H, et al. The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial. Health Promotion Perspectives. 2024;14(4):380-387. doi:10.34172/hpp.42486

BibTeX
@article{Najafipour2024,
  author = {Najafipour, Mostafa and Najafipour, Farzad and Ostadrahimi, Alireza and Ghavami, Maryam and Razaghi, Zohreh and Tutunchi, Helda and Mesri Alamdari, Naimeh},
  title = {The effects of empagliflozin in patients with type 1 diabetes: Results of a 12-week, double-blind, randomized, placebo-controlled clinical trial},
  journal = {Health Promotion Perspectives},
  year = {2024},
  volume = {14},
  number = {4},
  pages = {380--387},
  doi = {10.34172/hpp.42486}
}
Kostenlos starten →